Effects of fish oil supplementation on glucose control and lipid levels among patients with type 2 diabetes mellitus: a Meta-analysis of randomized controlled trials.
Adult
Aged
Blood Glucose
/ metabolism
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Diabetes Mellitus, Type 2
/ blood
Dietary Supplements
Fasting
/ physiology
Female
Fish Oils
/ administration & dosage
Glycated Hemoglobin
/ metabolism
Humans
Insulin
/ blood
Insulin Resistance
Male
Middle Aged
Randomized Controlled Trials as Topic
Triglycerides
/ blood
Fish oil
Meta-analysis
Omega-3 fatty acids
Randomized clinical trials
Type 2 diabetes mellitus
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
08 May 2020
08 May 2020
Historique:
received:
12
11
2019
accepted:
24
02
2020
entrez:
10
5
2020
pubmed:
10
5
2020
medline:
13
3
2021
Statut:
epublish
Résumé
Previous studies have yielded inconsistent findings on the role of fish oil in type 2 diabetes mellitus (T2DM). We systematically summarized the available evidence from randomized controlled trials (RCT) and aimed to investigate the effects of fish oil supplementation on glucose control and lipid levels among patients with T2DM. A comprehensive literature search was performed in electronic databases (PubMed, ProQuest, Cochrane Library, CNKI, VIP, and Wanfang) to identify all relevant RCTs which were published up to May 31st, 2019. We used Modified Jadad Score system to evaluate the quality of each included RCT. The pooled effects were estimated using random-effects model and presented as standardized mean differences with 95% confidence intervals. A total of 12 RCTs were included in this meta-analysis. There was no significant difference in glucose control outcomes comparing fish oil supplementation to placebo. The effect size of fasting plasma glucose (FPG) was 0.13 (95% CI: - 0.03 to 0.28, p > 0.05). No marked change was observed in fasting insulin (FINS), glycosylated hemoglobin (HbA1c), and HOMA of insulin resistance (HOMA-IR) levels. Fish oil supplementation was associated with a decrease of triglyceride (TG) level by - 0.40 (95%CI: - 0.53 to - 0.28, p < 0.05), and an increase of high density lipoprotein (HDL) cholesterol level by 0.21 (95%CI: 0.05 to 0.37, p < 0.05). In subgroup analysis, HDL cholesterol level was higher among Asian and low-dose(< 2 g/d n-3 PUFA) subgroups compared to their counterparts (p < 0.05). TG level was lower in mid and long duration groups, along with an inconspicuous difference in short duration group. This meta-analysis shows that among patients with T2DM, fish oil supplementation leads to a favorable blood lipids profile but does not improve glucose control.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have yielded inconsistent findings on the role of fish oil in type 2 diabetes mellitus (T2DM). We systematically summarized the available evidence from randomized controlled trials (RCT) and aimed to investigate the effects of fish oil supplementation on glucose control and lipid levels among patients with T2DM.
METHODS
METHODS
A comprehensive literature search was performed in electronic databases (PubMed, ProQuest, Cochrane Library, CNKI, VIP, and Wanfang) to identify all relevant RCTs which were published up to May 31st, 2019. We used Modified Jadad Score system to evaluate the quality of each included RCT. The pooled effects were estimated using random-effects model and presented as standardized mean differences with 95% confidence intervals.
RESULTS
RESULTS
A total of 12 RCTs were included in this meta-analysis. There was no significant difference in glucose control outcomes comparing fish oil supplementation to placebo. The effect size of fasting plasma glucose (FPG) was 0.13 (95% CI: - 0.03 to 0.28, p > 0.05). No marked change was observed in fasting insulin (FINS), glycosylated hemoglobin (HbA1c), and HOMA of insulin resistance (HOMA-IR) levels. Fish oil supplementation was associated with a decrease of triglyceride (TG) level by - 0.40 (95%CI: - 0.53 to - 0.28, p < 0.05), and an increase of high density lipoprotein (HDL) cholesterol level by 0.21 (95%CI: 0.05 to 0.37, p < 0.05). In subgroup analysis, HDL cholesterol level was higher among Asian and low-dose(< 2 g/d n-3 PUFA) subgroups compared to their counterparts (p < 0.05). TG level was lower in mid and long duration groups, along with an inconspicuous difference in short duration group.
CONCLUSIONS
CONCLUSIONS
This meta-analysis shows that among patients with T2DM, fish oil supplementation leads to a favorable blood lipids profile but does not improve glucose control.
Identifiants
pubmed: 32384902
doi: 10.1186/s12944-020-01214-w
pii: 10.1186/s12944-020-01214-w
pmc: PMC7206824
doi:
Substances chimiques
Blood Glucose
0
Cholesterol, HDL
0
Cholesterol, LDL
0
Fish Oils
0
Glycated Hemoglobin A
0
Insulin
0
Triglycerides
0
hemoglobin A1c protein, human
0
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Subventions
Organisme : National Natural Science Foundation of China
ID : No.81602858
Organisme : Young Elite Scientists Sponsorship Program by CAST
ID : No.YESS20160164, 2016QNRC001
Organisme : 2015 Chinese Nutrition Society (CNS) Nutrition Research Foundation-DSM Research Fund
ID : CNS2015067B
Références
Asia Pac J Clin Nutr. 2019;28(1):1-5
pubmed: 30896407
Lipids Health Dis. 2017 Jul 3;16(1):131
pubmed: 28673352
J Clin Lipidol. 2015 Nov-Dec;9(6):770-777
pubmed: 26687697
Am J Clin Nutr. 2006 Feb;83(2):331-42
pubmed: 16469992
N Engl J Med. 2018 Oct 18;379(16):1540-1550
pubmed: 30146932
Stroke. 2019 Feb;50(2):274-282
pubmed: 30602356
Nutr Clin Pract. 2012 Aug;27(4):553-60
pubmed: 22661243
Nutrients. 2017 Jun 03;9(6):
pubmed: 28587203
Metabolism. 2014 Jul;63(7):930-40
pubmed: 24850465
Nat Rev Endocrinol. 2018 Feb;14(2):88-98
pubmed: 29219149
Int J Vitam Nutr Res. 2010 Apr;80(2):107-16
pubmed: 20803425
JAMA Cardiol. 2018 Mar 1;3(3):225-234
pubmed: 29387889
Nutrients. 2017 Oct 06;9(10):
pubmed: 28984832
Nutrients. 2018 Jun 13;10(6):
pubmed: 29899246
Lancet. 2019 May 11;393(10184):1958-1972
pubmed: 30954305
J Am Coll Cardiol. 2018 Oct 2;72(14):1576-1584
pubmed: 30261957
N Engl J Med. 2019 Jan 3;380(1):23-32
pubmed: 30415637
PLoS One. 2015 Oct 02;10(10):e0139565
pubmed: 26431431
Diabetes Care. 1990 Aug;13(8):821-9
pubmed: 2209315
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9362-7
pubmed: 19474294
JAMA Intern Med. 2016 Aug 1;176(8):1155-66
pubmed: 27357102
Cardiovasc Diabetol. 2017 Apr 14;16(1):50
pubmed: 28410617
EBioMedicine. 2018 May;31:150-156
pubmed: 29703528
PLoS One. 2012;7(9):e44525
pubmed: 22984522
Cochrane Database Syst Rev. 2018 Nov 30;11:CD003177
pubmed: 30521670
BMJ. 2018 Oct 17;363:k4067
pubmed: 30333104
Lancet. 2017 Jun 3;389(10085):2239-2251
pubmed: 28190580
Circulation. 2018 Jul 3;138(1):e35-e47
pubmed: 29773586
Diabet Med. 2010 Jan;27(1):54-60
pubmed: 20121889
Ann N Y Acad Sci. 1993 Jun 14;683:272-8
pubmed: 8251021
Br J Nutr. 2012 Jun;107 Suppl 2:S214-27
pubmed: 22591895
Mol Nutr Food Res. 2010 May;54 Suppl 1:S112-9
pubmed: 19998382
Diabetes Care. 2017 Jul;40(7):813-820
pubmed: 28637886
Diabetes Care. 2002 Mar;25(3):417-24
pubmed: 11874924
Cardiovasc Diabetol. 2018 Jul 7;17(1):98
pubmed: 29981570
Cell. 2010 Sep 3;142(5):687-98
pubmed: 20813258
Diabetes Care. 1995 Jan;18(1):83-6
pubmed: 7698053
Am J Clin Nutr. 2007 Dec;86(6):1670-9
pubmed: 18065585